Rick Wise

Boston Scientific’s Ingenio Pacemaker Wins U.S. FDA Approval

Boston Scientific Corp.’s Ingenio and Advantio pacemakers won U.S. approval to treat abnormally slow heartbeats, clearing the way for sales of devices that have been in development for a decade in the $4 billion global market.

Boston Scientific Heart Device May Malfunction, Wise Says

Boston Scientific Corp.’s Cognis and Teligen defibrillators, used to shock hearts into a normal rhythm, may have a flaw that’s has been linked to a death, said Rick Wise, an analyst with Leerink Swann & Co.

Hospira Falls After Cutting Annual Forecast on Plant Costs

Hospira Inc., a maker of generic injectable drugs, declined the most ever after the company reduced its annual earnings forecast to reflect costs to improve manufacturing at a North Carolina factory.

J&J Third-Quarter Profit Gains on Drug, Device Sales

Johnson & Johnson , the world’s largest health-products company, reported third-quarter revenue that missed analysts’ estimates as recalls of children’s medicines hurt sales of consumer products.

Hospira Becoming Generic Drug Takeover Target With FDA Scrutiny: Real M&A

Hospira Inc., embroiled in regulatory scrutiny for flaws in its manufacturing practices, has become so cheap that buyers may now pounce to claim a third of the world’s market for specialty generic injectable drugs.

J&J Lowers Annual Forecast on Impact of Drug Recalls

Johnson & Johnson fell the most in six weeks in New York trading after the company, the world’s largest maker of health products, lowered its full-year earnings forecast because of a series of over-the-counter drug recalls.

J&J Names Alex Gorsky CEO to Replace William Weldon

Johnson & Johnson’s insider pick of Alex Gorsky as the new chief executive officer elevates the person most familiar with the safety and quality issues that have plagued the company.

J&J Profit Rises on Improved Device Sales

Johnson & Johnson, the world’s biggest health-products company, reported a 29 percent increase in first-quarter profit, boosted by a gain from litigation and higher sales of surgical tools and Listerine mouth wash.

Zimmer, Stryker May Seek Orthopedic Purchases to Keep Pace After J&J Deal

Johnson & Johnson’s newfound dominance of the orthopedic-device market, cemented by its $21.3 billion acquisition of Synthes Inc. , may drive rivals Zimmer Holdings Inc. and Stryker Corp. to seek purchases of their own.

Abbott Laboratories Slips as Fourth-Quarter Sales Come in Below Estimates

Abbott Laboratories, the health-care company that plans to spin off its drug business, fell the most in two months after reporting fourth-quarter sales that came in below analyst estimates.

"It's been a challenging time for devices, but not through any of Alex's doing."

- Rick Wise on Feb 21, 2012

New York

New Brunswick

Europe

Food And Drug Administration

Europe Stocks Fall With S&P 500 Futures as Yen Fluctuates

Pakistan Stocks Rise to Record as Sharif Approaches Election Win

China’s Investment Slows as Production Trails Estimates: Economy

U.S., Japan, Australia Bonds Tumble on Stimulus Efforts

Rally Matches 1990s Web-Fed Gains With Valuations 28% Lower